• Adherence to response-guided pegylated interferon and ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: The ACTIVATE study 

      Cunningham, Evan B; Hajarizadeh, Behzad; Dalgard, Olav; Amin, Janaki; Hellard, Margaret; Foster, Graham R; Bruggmann, Philip; Conway, Brian; Backmund, Markus; Robaeys, Geert; Swan, Tracy; Marks, Philippa S; Quiene, Sophie; Applegate, Tanya L; Weltman, Martin; Shaw, David; Dunlop, Adrian; Bruneau, Julie; Midgard, Håvard; Bourgeois, Stefan; Thurnheer, Maria Christine; Dore, Gregory J; Grebely, Jason; Shaw, Ineke; Siriragavan, Sharmila; Horschik, Tina; Sharma, Shawn; Eevers, Anita; Andreassen, Jessica; Melkeraaen, Ingunn; Widder, Nicole; Lesneuck, Kristof; Kotsoros, Barbara; Hazelwood, Susan; Holland, Rohan; Axten, David; Von Bibra, Sally; Powis, Jeff; Mason, Kate; Ryder, Stephen; Jack, Kate; Scheidegger, Claude; Huber, Christine; Ferguson, Catherine; Staehelin, Cornelia; Lacalamita, Melanie; Fragomeli, Vincenzo; Sevehon, Alison (BMC Infectious Diseases;17(1), Journal article; Peer reviewed, 2017-06-13)
      Background The aims of this analysis were to investigate treatment completion and adherence among people with ongoing injecting drug use or receiving opioid substitution therapy (OST) in a study of response-guided therapy ...
    • Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial 

      Grebely, Jason; Dalgard, Olav; Conway, Brian; Cunningham, Evan B.; Bruggmann, Philip; Hajarizadeh, Behzad; Amin, Janaki; Bruneau, Julie; Hellard, Margaret; Litwin, Alain H.; Marks, Phillippa; Quiene, Sophie; Siriragavan, Sharmila; Applegate, Tanya L.; Swan, Tracy; Byrne, Jude; Lacalamita, Melanie; Dunlop, Adrian; Matthews, Gail V.; Powis, Jeff; Shaw, David; Thurnheer, Maria Christine; Weltmann, Martin; Kronborg, Ian; Cooper, Curtis; Feld, Jordan J.; Fraser, Chris; Dillon, John F.; Read, Phillip; Gane, Edward; Dore, Gregory J. (The lancet Gastroenterology & hepatology;3(3), Journal article; Peer reviewed, 2018-03)
      Background Despite revised guidelines that no longer exclude people who inject drugs (PWID) from treatment for hepatitis C virus (HCV) infection, many clinicians are reluctant to treat recent PWID. This study aimed to ...